Cargando…

Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes

EGFR-TKIs were used in NSCLC patients with actionable EGFR mutations and prolong prognosis. However, most patients treated with EGFR-TKIs developed resistance within around one year. This suggests that residual EGFR-TKIs resistant cells may eventually lead to relapse. Predicting resistance risk in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Xiaohong, Li, Lifeng, Xie, Liang, Liu, Zhentian, Zhang, Guoliang, Gao, Xuan, Peng, Wenying, Deng, Haiyi, Yang, Yilin, Yang, Meiling, Chang, Lianpeng, Yi, Xin, Xia, Xuefeng, He, Zhiyi, Zhou, Chengzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241979/ https://www.ncbi.nlm.nih.gov/pubmed/37288343 http://dx.doi.org/10.1016/j.isci.2023.106584

Ejemplares similares

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Successful management of Epstein‑Barr virus‑associated severe checkpoint inhibitor‑related pneumonitis: A case report
por: Deng, Jiaxi, et al.
Publicado: (2023)

Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report
por: Qiu, Guihuan, et al.
Publicado: (2022)

A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
por: Qiu, Guihuan, et al.
Publicado: (2023)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
por: Lin, Xinqing, et al.
Publicado: (2021)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer
por: Xie, Xiaohong, et al.
Publicado: (2022)

Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing
por: Liang, Chaoyue, et al.
Publicado: (2018)

Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations
por: Hong, Guodai, et al.
Publicado: (2019)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature
por: Zhang, Xiaobo, et al.
Publicado: (2022)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
por: Tian, Yingying, et al.
Publicado: (2018)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Effect and mechanism of miR-146a on malignant biological behaviors of lung adenocarcinoma cell line
por: Yuan, Fang, et al.
Publicado: (2020)

Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Jiang, Jiahong, et al.
Publicado: (2021)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review
por: Lin, Xinqing, et al.
Publicado: (2019)

Incorporating radiomic feature of pretreatment (18)F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma
por: Chen, Yu-Hung, et al.
Publicado: (2020)

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
por: Lin, Xinqing, et al.
Publicado: (2021)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Erratum to: The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer
por: Zhou, Zhiyi, et al.
Publicado: (2015)

Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
por: Lin, Xinqing, et al.
Publicado: (2021)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer
por: Li, Suyang, et al.
Publicado: (2022)

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
por: Lv, Yang, et al.
Publicado: (2016)

The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
por: Guan, Jun, et al.
Publicado: (2018)

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy: A case report
por: Zhang, Qianyu, et al.
Publicado: (2022)

Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review
por: Xi, Yun-Zhu, et al.
Publicado: (2022)

Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma
por: Wang, Fei, et al.
Publicado: (2020)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
por: Xu, Zhanyu, et al.
Publicado: (2021)

Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
por: Lin, Xinqing, et al.
Publicado: (2022)

Real-world data on severe lung cancer: a multicenter retrospective study
por: Wang, Fei, et al.
Publicado: (2023)

STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway
por: Xu, Hui, et al.
Publicado: (2021)

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
por: Yang, Yang, et al.
Publicado: (2017)

High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival
por: Wang, Daiyong, et al.
Publicado: (2017)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ulj9p9lkpkste0tb3hl3oa1e6j